reason report
bottom line iterum develop iv oral formul
sulopenem uncompl complic urinari
tract infect uti complic intra-abdomin infect
sulopenem target two key unmet need new antibiot
target rise resist rate fluoroquinolon
oral penem allow earlier patient discharg iv oral
molecul class base triangul data point
believ sulopenem better even odd success
head phase expect read
data posit sulopenem approv believ
differenti profil could gener sale
risk-adjust come urinari tract infect
come oral larg patient popul
predominantli treat gener rise resist
rate current treatment rang believ total
address market size believ sulopenum
gain meaning share initi coverag itrm
outperform rate price target
major sulopenem valu resid oral option
treat uti valuat resid
uncompl complic urinari tract infect given believ
approxim offic hospit visit per year
indic respect also valuat resid
oral formul allow patient discharg earlier
remain class antibiot furthermor given rise
rate fluoroquinolon resist addit oral antibiot help fill
unmet need outpati inpati set
believ likelihood success phase
studi base triangul data use framework
key question use predict success op omadacyclin
link appli framework itrm sulopenem came
away cautious optimist key risk ahead phase data resid
well oral formul replic earli clinic efficacy/
safeti data iv sulopenem seen phase japanes patient base
key driver efficaci time mean inhibitori concentr
iv oral formul low protein bind
sulopenem management commentari oral drug convert
pro-drug gut mimic iv formul cautious
optimist oral formul success
valuat base dcf methodolog project cash
flow termin valu use discount rate
in-lin clinic stage anti-infect compani
methodolog dcf analysi discount rate
termin valu
net debt total capit
gener unless otherwis note
compani inform leerink partner llc research
revenu mm
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rx trend deriv im health
iterum itrm initi coverag outperform rate
place outperform rate iterum therapeut itrm appli price target share lead
product sulopenem penem-class antibiot iv oral formul develop treat
complic cuti uncompl uuti urinari tract infect complic intra-abdomin infect
ciai believ oral formul sulopenem well receiv hospit transit set addit
treat resist outpati set see itrm gener sale risk-
deriv pt use dcf project cash flow termin valu use
discount rate in-lin clinic stage anti-infect compani coverag univers akao
risk valuat
sulopenem may success phase trial iterum may face difficulti commerci
dilut risk compani may need addit capit beyond current assum
iterum therapeut major valuat resid oral formul sulopenem
known safeti efficaci usual reserv
last line use
oral formul sulopenem contribut
major valuat wide use
iv-or step-down roughli penem
understood valu proposit physician
view major sulopenem use
hospit transit set small share
outpati set uti specif patient
potenti resist pathogen still healthi
enough oral option vs hospit
initi phase studi uuti cuti ciai
top-lin data three studi
risk invest thesi valuat
deriv pt use dcf project
cash flow termin valu
use discount rate in-lin
clinic stage anti-infect compani
clinic risk sulopenem may meet success
commerci risk compani may face difficulti
posit clinic data sulopenem drive stock
leerink estim factset note market cap million average volum thousand
iterum therapeut plc
sulopenem sale royalti indic
iterum form former manag
team durata therapeut
compani focu develop novel
led develop sulopenem
instrument in-licens
asset pfizer
compani one product sulopenem
enter ph
potent safe broad spectrum antibiot
iv oral formul allow
qidp statu allow data
exclus patent
global right asset
uuti cuti ciai
phase start
iterum led experienc manag team experi
durata acquir actavi roughli multipl take-out
appli consensu estim sale take-out price
lead asset dalvanc singl weekli iv inject skin infect
nametitlebackgroundcorey fishmanceoformerli cfo inc led ipo secondari offer includ negoti sale compani actavi plc prior durata cfo current serv board momenta pharmaceut michael dunn mdcsoformerli inc remain leadership role actavi plc upon sale durata prior durata dr dunn serv varieti role pfizer judith matthewscfoformerli vice-president financ inc acquisit actavi prior durata head financi plan analysi balli total fit jeff schaffnitccojoin iterum prior iterum group vice-president head patient engag shire mr schaffnit held leadership role baxalta baxter focus hematolog busi iterum therapeut plc
downsid
revenu risk-adjust use po
revenu driven oral formul
revenu deriv urinari tract infect uti
believ oper turn profit time-frame
net capit rais recent announc anticip post-
ipo cash believ suffici fund oper
expect compani addit rais post-posit phase
data fund commerci
expect next key catalyst
initi three phase studi uuti cuti ciai
top-lin data three studi
nda submiss sulopenem three indic
phase uuti cuti data prtk omadacyclin
project cash flow three year assum patent
expir assum composit matter patent oral
sulopenem get extens hatch-waxman
dcf valuat assum termin valu discount rate
also account addit share issu potenti
compani report leerink estim
debat stock much comfort obtain oral
penem-class antibiot efficaci driven time minimum inhibitori
oral
concentr penem meropenem ertapenem
demonstr impli time plasma concentr
higher per hr
iv sulopenem demonstr impli hr time
plasma concentr higher per hr suffici efficaci
singl dose oral sulopenem probenecid demonstr hr
impli bid dose suffici demonstr efficaci
compani assess oral bid dose pk/pd data iv bid
dose patient level found differ
triangul data point give us optim oral formul
iv qd dose demonstr similar iv bid dose
risk ad
dose
chang
qd bid
phase
test japanes patient
phase iv bid demonstr efficaci japanes patient
howev studi conduct nearli two decad ago
management comment patient-by-pati level japanes
caucasian patient two dose regimen look similar regardless patient
two point give us optim dose chang impact efficaci
sulopenem
compani report leerink estim
debat stock much comfort obtain oral
resist rate commonli use antibiot option uti
new
fluoroquinolon beta-lactam antibiot use wide uti treatment
per cddep resist rate fluoroquinolon us reach
even higher rate certain geographi
sulopenem potenti first oral penem approv allow earlier
patient discharg step-down therapi mechan
provid step-down option reson hospit physician
enabl potenti earlier discharg hospit class antibiot
discharg class antibiot fit antibiot stewardship strategi
per iqvia least script iv penem antibiot dispens
draw
garner
confid
per decis resourc nearli patient given carbapenem
counter rise resist rate uti patient data annual half-
compani report leerink estim cddep center diseas dynam econom polici
iterum conduct phase registr studi spa fda
requir singl studi per indic approv
sulopenem
cure day
clinic microbiolog
test cure
sulopenem
hr
min
cure day
clinic microbiolog
ema support ertapenem
test cure
sulopenem
hr
min
bid metronidazol
cure day
test cure
uuti studi assess non-inferior ni margin ciprofloxacin also hierarch
analysi assess superior ciprofloxacin ciprofloxacin resist popul
cuti ciai studi assess ni margin
iterum end phase
framework assess success phase look key question
date iterum gener clinic data efficaci oral formul
sulopenem order garner confid phase studi reason
chanc success seek answer key question
vitro profil sulopenem look relev uti iai pathogen
word drug kill bacteria primari driver two
pharmacokinet question drug level relev area bodi
blood urin etc pk iv oral compar
data gener date preced antibiot
class succeed uti iai
much comfort sulopenem safeti profil
sulopenem activ key pathogen drive urinari tract infect
intra-abdomin infect
sulopenem demonstr less key
pathogen caus uuti cuti ciai
defin
fda guidanc document uuti cuti ciai list specif pathogen
per literatur pathogen common caus infect
sulopenem provid encourag evid drug effect
infect type caus pathogen
preclin efficaci often translat clinic efficaci provid drug reach
tissues/fluid involv infect
oral demonstr suffici time key driver penem efficaci
earli data suggest success await clinic data
time key driver penem efficaci data oral sulopenem suggest
dose twice day replic seen iv sulopenem
clinic data efficaci gener date oral formul
triangul differ data point provid optim success
penem-class antibiot determin efficaci drug
base success phase japanes studi bid iv dose demonstr
qd iv dose caucasian patient also demonstr
oral replic qd iv two dose sulopenem
probenecid fast state fed state
furthermor itrm compar data oral dose found similar paramet
seen japanes patient
oral prodrug management comment oral formul behav like iv sulopenem
convert gi tract
investig assess outcom jpn phase studi suggest equival
efficaci iv sulopenem imipenem post-hoc analysi
sulopenem seen activ cuti compar efficaci imipenem penem
sulopenem activ activ ciai hard interpret data without compar
japanes phase studi pool hoc analysi
penem approv intra-abdomin urinari tract infect
penem approv wide use treat abdomin urinari tract
infect thu sulopenem like use indic
drug/indicationsimipenemdoripenemertapenemmeropenemintra-abdomin infectionsxxxxurinari tract infectionsxxxgynecolog infectionisxxlow respiratori tract infectionsxxbon joint infectionsxskin skin structur infectionsxxx iterum plc
caveat cross-trial comparison sulopenem seem equal
effect vs broad spectrum antibiot use ciai cuti
sulopenem activ seem par penem key antibiot use treat
ciai cuti
comparison approv penem-class two key quinolone-class agent
sulopenem highlight efficaci seen date iv formul par
howev sulopenem data post-hoc analysi conduct japanes
meropenemertapenemdoripenemsulopenemlevofloxacinciprofloxacinciai clinic bidcuti clinic product insert iterum studi iterum therapeut plc
sulopenem test pt similar safeti profil penem
sulopenem demonstr similar safeti profil cefotiam imipenem pool
data collect us japanes patient
balanc attribut po sulopenem ahead phase data
ultim probabl success po sulopenem rest
efficaci iv sulopenem demonstr phase studi japanes
patient work done demonstr pk/pd equival
iv qd similar iv bid use japanes patient final
oral bid replic iv qd iv bid
sulopenem demonstr preclin efficaci major pathogen
drive uti iai
sulopenem test patient japanes
caucasian demonstr safeti profil similar penem
commerci potenti
rise resist current class broad-spectrum antibiot
underscor need new antibiot option
use penem increas provid immedi opportun oral penem
penem use uti rise underscor issu rise resist rate current option
patient penem prescript
physician favor concept continu molecul use class
antibiot iv oral
histor blockbust antibiot iv oral formul
iv oral formul class antibiot also reson
hospit payer provid strong pharmacoeconom valu proposit
sulopenem remain differenti light competit develop uti and/or ciai
uuti sulopenem face competit prtk omadacyclin potenti akao
cuti sulopenem face multipl competitor howev drug plazomicin vabomer
cefiderocol target nich indic highli resist pathogen
util cuti registr pathway
ciai major option iv-formul render sulopenem potenti differenti
biomedtrack leerink partner research
drugformulationcompanytickerphas lead indicationlead indic indic delafloxaciniv oralapprov oralparatekprtkndacabp absssiuuti cutiplazomiciniv ndacuticreceftibuten clavulanateoralicutiesbl utieravacyclineivtetraphasettphndaciairelebactam-imipenemivmerckmrkiiiciaiatm-aviivallerganagniiciaiteflaro-avibactamivallerganagniiabsssicutitebipenem ciai iterum plc
view target address market across three indic
assum iterum captur revenu oral
uuti opportun patient high risk comorbid elderli resist suspect
cuti opportun step-down option iv penem resist suspect
pt iv
ciai opportun step-down option iv penem resist suspect
pt iv
et al diagn microbiol infect assist secretari plan evalu hh data literatur rate corrobor im script data cddep org coli pneumonia
view attribut minim iv sale sulopenem
cuti opportun small share iv sulopenem resist suspect
pt iv
ciai opportun small share iv sulopenem resist suspect
pt iv
assist secretari plan evalu hh data
medacorp kol feedback suggest potenti meaning use sulopenem
continu molecul unmet need standpoint
feedback
lack oral
need
lack avail oral agent leav decid whether
admit patient get iv antibiot get outpati iv antibiot
around complic uti patient discharg
picc line order facil outpati iv antibiot pose risk
infect
around cuti patient get iv penem oral option would
allow us discharg class molecul
patient recur uti infect usual treat patient
iv penem
area practic patient resist cipro
resist tmx bactrim im limit use macrolid
given new warn elderli pulmonari side effect
dont think sulopenem given antibiot stewardship strategi would use
line line proven resist isol
believ sulopenem grow un-risk adjust sale
sulopenem sale royalti market share infect indic
sale royalti million percent market share
sulopenem market share indic
indic
compani report leerink estim
upside/downsid scenario iterum therapeut itrm
compani report leerink estim
initi phase uuti
cuti ciai studi
compani report leerink estim
risk invest thesi
phase studi uuti cuti ciai could neg
major valu oral sulopenem could demonstr miss non-
uuti cuti repres largest driver valu
class
slower
sulopenem could competit antibiot oral formul
class antibiot could push penem use back reduc
hospit formulari payer may requir step-edit use brand
compani report leerink estim
number except per share data
gener administr
sale market
net debt ebitda ratio
note share outstand ipo assum weight averag share count base may date price
number except per share data
sulopenem product sale indic po adj
sulopenem product royalti indic po adj
total sulopenem sale indic risk-adjust
number except per share data
prepaid expens current
properti equip net
deposit asset
number except per share data
adjust reconcil ni net cash oper
amort premium short-term invest
loss gain dispos fix asset
decreas increas work capit
purchas properti equip
purchas short term invest
matur short term invest
net invest
proceeds/repay loan payabl
net financ
net chang equival
uncompl uti esbl
uuti esbl
patient treat oral sulopenem
uuti patient oral sulopenem
oral sulopenem treat patient uuti
averag day oral therapi
net oral sulopenem
oral sulopenem sale uuti
probabl success
p/w sulopenem sale uti us
p/w sulopenem royalti uti row
probabl success
assum net sulopenem/day
assum day therapi
compani report leerink partner research
iv sulo use hospit patient
cuti hospit
patient hospit cuti
patient treat iv sulopenem
cuti patient iv sulopenem
total cuti share iv sulopenem
averag day iv therapi
net iv sulopenem
iv sulopenem sale uti
iia oral sulo step hospit patient
oral sulo step iv penem
patient hospit cuti
treat iv penem mero erta etc
patient treat iv penem
oral sulo step iv sulo
patient treat iv penem
patient treat iv penem iv sulo
patient iv step-down oral sulo
patient step-down oral sulo
cuti hospit
patient hospit cuti
treat oral sulo
non-hospit cuti oral sulo
total patient oral sulopenem
total cuti share oral sulo
average day oral therapi
net oral sulopenem
oral sulopenem sale uti
probabl success
p/w sulopenem sale uti us
p/w sulopenem royalti uti row
probabl success
assum net iv sulopenem/day
assum day iv therapi
assum net oral sulopenem/day
assum day oral therapi
compani report leerink partner research
ciai hospit
patient hospit ciai
patient treat iv sulopenem
total ciai share iv sulopenem
ciai patient iv sulopenem
averag day iv therapi
net iv sulopenem
gross iv sulopenem sale ciai
patient hospit ciai
treat iv penem mero erta etc
patient treat iv penem iv sulo
patient iv step-down oral sulo
patient step-down oral sulo
total ciai treat oral sulo
non-hospit ciai oral sulo
total ciai share oral sulo
total patient oral sulopenem
average day oral therapi
net oral sulopenem
gross oral sulopenem sale ciai
probabl success
p/w sulopenem sale ciai us
p/w sulopenem royalti ciai row
probabl success
assum net iv sulopenem/day
assum day iv therapi
assum net oral sulopenem/day
assum day oral therapi
compani report leerink partner research
number except per share data
chang work capit
